Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
822 articles with Ionis Pharmaceuticals, Inc.
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises. He will report to Richard
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 39th Annual J.P. Morgan Healthcare Conference at 3:40 p.m. ET on Tuesday, January 12, 2021.
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Crooke, M.D., Ph.D., will retire from Ionis and its board of directors effective June 2021
At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. highlighted the company's significant achievements in 2020 and outlined its strategy to realize the substantial opportunity of its pipeline.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside chat at the BMO 2020 Growth and ESG Conference at 3:00 p.m. E.T. on Tuesday, December 8, 2020 .
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is a debilitating genetic disease characterized by severely high plasma levels of triglycerid
Ionis Pharmaceuticals, Inc. announced that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Eastern Time to provide an overview of its commercial strategy, key opportunities in its cardiovascular and neurological franchises and recent technology advances.
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9),
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
Ionis' novel antisense medicine targeting PCSK9 demonstrates best-in-class potential for the treatment of patients with high cholesterol at risk for cardiovascular disease
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference, to be held virtually Nov. 11-13, 2020.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences:
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights.
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs).
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI, the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloidosis in adults.
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
Tofersen and IONIS-C9Rx also currently in clinical trials targeting genetic forms of the disease
Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress.
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Study will evaluate the effectiveness of IONIS-PKK-LRx in reducing the severity of respiratory complications in COVID-19 patients
Data from the first clinical study of IONIS-ENAC-2.5 Rx to be presented at North American Cystic Fibrosis Conference